HIV

South Africa’s youth are a generation lost under democracy – study

Retrieved on: 
Thursday, April 25, 2024

But what is the real state of young South Africans – defined as people below the age of 34 – after 30 years of democracy?

Key Points: 
  • But what is the real state of young South Africans – defined as people below the age of 34 – after 30 years of democracy?
  • My recent research paper tracing 30 years of analysing youth marginalisation has found that youth in South Africa, who make up 34.3% of the population, have not fared well under democracy.

Measuring marginalisation

  • The survey recorded indicators like unemployment and level of education, as well as subjective views like feelings of alienation (not belonging in society).
  • The results were arranged on a scale of how far some young people had been pushed to the margins of society.
  • Comparing data from the 1992 and 2018 indices of youth marginalisation, the same proportion (5%) is clearly “lost” – scoring off the chart on virtually every indicator.
  • In terms of how much potential South Africa has squandered, they represent an entire generation of opportunity lost to the country.

Marginalised but not lost

  • As ever, they demonstrated their instrumental value to the adults controlling violence on various sides.
  • Those same adults and the media spoke of a “lost generation” – specifically, black, male, urban youth.

Marginalisation over time

  • In 1993, after first presenting to assembled youth organisations in 1992, we released the first iteration of the marginalisation index, Growing up Tough.
  • Despite the belief of our church sponsors that no-one is ever truly “lost”, that became the central category of the index.
  • In all, 5% of respondents scored high on all, or most, of the indicators in the 12 dimensions.
  • Most of the items in the index were later used by the Gauteng City Region Observatory in its early Quality of Life survey, allowing analysis of marginalisation across the entire Gauteng province population.
  • Only 0.3% of white youth (and 0.5% of Indian youth) showed signs of high marginalisation.


David Everatt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Taking stock of existing barriers to sexual and reproductive health of girls and women in SSA and how collaboration and innovation can help shape the future

Retrieved on: 
Wednesday, April 10, 2024

For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.

Key Points: 
  • For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.
  • Coupled with HIV, complications during pregnancy and childbirth are the leading cause of death for young women aged 15-19 years.
  • "Tiko" which provides access to free reproductive health services that can change the course of many lives offering youth-friendly care and comprehensive information.
  • Achieving universal access to sexual and reproductive health and rights by 2030 will require close collaboration by stakeholders in developing innovative solutions that can dismantle barriers to access among women and girls.

The Canadian Centre on Substance Use and Addiction Welcomes Scott Elliott to its Board of Directors

Retrieved on: 
Monday, April 8, 2024

“Scott is known for his efforts in tackling substance use health issues and finding unique, powerful solutions.

Key Points: 
  • “Scott is known for his efforts in tackling substance use health issues and finding unique, powerful solutions.
  • Mr. Elliott is the Chief Executive Officer of the Dr. Peter Centre in Vancouver, B.C.
  • The Centre provides clinical, social and psychological support to marginalized community members living with HIV, complex medical conditions, mental illness, and substance use and addictions.
  • “People in Canada will benefit from Scott’s understanding of community building and the diverse experiences across substance use health.”
    Mr. Elliott joins 12 other directors to complete CCSA’s volunteer Board of Directors.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
Monday, April 8, 2024

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
Thursday, April 4, 2024

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use

Retrieved on: 
Wednesday, April 3, 2024

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.

Key Points: 
  • Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use
    NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada .
  • This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.
  • The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients.
  • José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Retrieved on: 
Wednesday, April 3, 2024

The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.

Key Points: 
  • The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.
  • “Following our pre-NDA discussion with the FDA related to the path to approval for IkT-001Pro in up to 11 blood and stomach cancers in January, we requested an additional FDA meeting with the Division of Cardiology and Nephrology to discuss Pro as a treatment for Pulmonary Arterial Hypertension,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • “PAH is a rare condition that primarily afflicts women between the ages of 30 and 60 and can lead to premature heart failure and death.
  • We believe that Pro may be a be a safer and better tolerated therapeutic option for imatinib treatment in PAH.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team

Retrieved on: 
Tuesday, April 9, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240408262170/en/
    Tiffany Marg & Steph Carman (Photo: Business Wire)
    Tiffany has over 20 years of experience in pharmaceutical marketing, building brands and executing campaigns.
  • In her previous role as SVP of Client Services, Tiffany was dedicated to building a first-class service team for Underscore’s clients, ensuring alignment between their ongoing business needs and goals and the execution of Underscore’s strategy and solutions.
  • Tiffany stated, “I am proud of the team we’ve built to lead our client engagements at Underscore and am excited for this next opportunity.
  • I originally came to Underscore because I was passionate about ensuring alignment between clients’ business objectives, brand and creative strategy, and media engagement strategy.